Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 41,760 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total transaction of $10,911,052.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Xiaodong Wang also recently made the following trade(s):
- On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68.
Beigene Stock Up 0.5 %
Shares of NASDAQ ONC traded up $1.22 during trading hours on Monday, hitting $253.20. The company's stock had a trading volume of 565,258 shares, compared to its average volume of 447,630. Beigene, Ltd. has a 12 month low of $126.97 and a 12 month high of $287.88. The stock has a market capitalization of $24.91 billion, a PE ratio of -30.73, a PEG ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.
Beigene (NASDAQ:ONC - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The business had revenue of $1.13 billion for the quarter, compared to analysts' expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Sell-side analysts forecast that Beigene, Ltd. will post -5.82 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms have weighed in on ONC. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a research note on Thursday, March 13th. Macquarie boosted their target price on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Guggenheim restated a "buy" rating on shares of Beigene in a research report on Friday, February 28th. JMP Securities set a $348.00 price objective on Beigene in a research report on Friday, February 28th. Finally, Bank of America raised Beigene from a "neutral" rating to a "buy" rating and increased their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd.
Read Our Latest Analysis on ONC
About Beigene
(
Get Free Report)
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Read More
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
